Anne Louise Askou
VISION: Vetting the impact of Sortilin In Ocular Neovascularization
Wet age-related macular degeneration (AMD) is a leading cause of vision loss among people over 50 years old. Current treatments target a single growth factor, but many patients still lose vision, showing the need for new approaches. This project explores a multifunctional protein called sortilin, previously linked to neurodegenerative diseases, which we have found to be increased in immune and retinal support cells within damaged areas of the retina and appears to promote abnormal blood vessel growth and inflammation. By targeting sortilin, we aim to show that we can rescue disease-related changes and improve treatment outcomes. Ultimately, these insights may pave the way for better therapies not only for patients with AMD, but also for other retinal disorders.
